A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors

Journal of Immunotherapy
Catherine GérardJamila Louahed

Abstract

The PRAME tumor antigen is a potential target for immunotherapy. We assessed the immunogenicity, the antitumor activity, and the safety and the tolerability of a recombinant PRAME protein (recPRAME) combined with the AS15 immunostimulant (recPRAME+ AS15) in preclinical studies in mice and Cynomolgus monkeys. Four groups of 12 CB6F1 mice received 4 injections of phosphate-buffered saline (PBS), recPRAME, AS15, or recPRAME+AS15. Immunized mice were injected with tumor cells expressing PRAME (CT26-PRAME) 2 weeks or 2 months after the last injection. The mean tumor surface was measured twice a week. Two groups of 10 monkeys received 7 injections of saline or recPRAME+ AS15. T-cell responses were measured by flow cytometry using intracellular cytokine staining (ICS). In CB6F1 mice, repeated injections of recPRAME+ AS15 induced high PRAME-specific antibody titers and mostly CD4+ T cells producing cytokines. This immune response was long-lasting in these animals and was associated with protection against a challenge with PRAME-expressing tumor cells (CT26-PRAME) applied either 2 weeks or 2 months after the last injection; these data indicate the induction of an immune memory. In HLA-A02.01/HLA-DR1 transgenic mice, recPRAME+ AS15 induc...Continue Reading

References

Nov 9, 2005·Molecular Cancer Therapeutics·Dan A LaheruElizabeth M Jaffee
Apr 27, 2007·Immunity·Gianna Elena HammerNilabh Shastri
Jun 21, 2008·The New England Journal of Medicine·Olivera J Finn
Apr 2, 2010·Seminars in Immunology·Cheryl Lai-Lai ChiangGeorge Coukos
May 22, 2010·Seminars in Immunology·Thomas W Dubensky, Steven G Reed
Jul 29, 2010·Advances in Experimental Medicine and Biology·Christopher W Cluff
Aug 23, 2011·Expert Review of Vaccines·Josianne Nitcheu Tefit, Vincent Serra
Sep 29, 2011·The Cancer Journal·Michael PostowJedd D Wolchok
Nov 29, 2011·Cancer Immunology, Immunotherapy : CII·Marijo Bilusic, James L Gulley

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence-activated cell sorting
transfection
enzyme-linked immunosorbent assay
flow cytometry
FCS
FACS
transgenic

Clinical Trials Mentioned

NCT01159964
NCT01149343

Software Mentioned

Diva
Cellquest

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.